Get started
Author

Roberto Gómez

Observed names: R Gómez, R. Gomez, R.E. Gómez, Roberto E Gomez, Roberto E. Gomez, Roberto E. Gómez, Roberto Gomez
Institution: Elea (Argentina)
ORCID: 0000-0003-4979-0034
Observed ORCID: 0000-0003-4979-0034
OpenAlex ID: A5101449078
CIGB-300, a novel proapoptotic peptide that impairs the CK2 phosphorylation and exhibits anticancer properties both in vitro and in vivo
2008 · Silvio E. Perea, Osvaldo Reyes, et al. · Molecular and Cellular Biochemistry · 102
NGcGM3 Ganglioside: A Privileged Target for Cancer Vaccines
2010 · Luis E. Fernandez, Mariano R. Gabri, et al. · Journal of Immunology Research · 88
PDF
Safety and preliminary efficacy data of a novel Casein Kinase 2 (CK2) peptide inhibitor administered intralesionally at four dose levels in patients with cervical malignancies
2009 · Ana M Solares, Agueda Santana, et al. · BMC Cancer · 80
PDF
Anticancer peptide CIGB-300 binds to nucleophosmin/B23, impairs its CK2-mediated phosphorylation, and leads to apoptosis through its nucleolar disassembly activity
2009 · Yasser Perera, Hernán G. Farina, et al. · Molecular Cancer Therapeutics · 70
Systemic administration of a peptide that impairs the protein kinase (CK2) phosphorylation reduces solid tumor growth in mice
2007 · Yasser Perera, Hernán G. Farina, et al. · International Journal of Cancer · 65
PDF
CIGB-300, a synthetic peptide-based drug that targets the CK2 phosphoaceptor domain. Translational and clinical research
2011 · Silvio E. Perea, Idania Baladron, et al. · Molecular and Cellular Biochemistry · 45
Cost-effectiveness of influenza vaccination in high-risk children in Argentina
2001 · Gustavo H Dayan, Van Hung Nguyen, et al. · Vaccine · 43
A phase II dose-escalation trial of perioperative desmopressin (1-desamino-8-d-arginine vasopressin) in breast cancer patients
2015 · Ruth S Weinberg, Marcelo O Grecco, et al. · SpringerPlus · 42
PDF
Optimizing CIGB-300 intralesional delivery in locally advanced cervical cancer
2015 · for the CERVIFARM-300-II Study Group, M R Sarduy, et al. · British Journal of Cancer · 37
PDF
Sensitivity of tumor cells towards CIGB‐300 anticancer peptide relies on its nucleolar localization
2012 · Yasser Perera, Heydi C. Costales, et al. · Journal of Peptide Science · 32
PDF
CIGB-300, a proapoptotic peptide, inhibits angiogenesis in vitro and in vivo
2011 · Hernán G. Farina, Fernando Benavent Acero, et al. · Experimental Cell Research · 24
Anti-idiotype antibodies in cancer treatment: the pharmaceutical industry perspective
2012 · Roberto E. Gómez, Maria L. Ardigo · Frontiers in Oncology · 10
PDF
Phase I Study of CIGB-300 AdministeredIntravenously in Patients with Relapsed/Refractory Solid Tumors
2018 · Noyde Batista-Albuerne, Lidia González-Méndez, et al. · 8
CIGB-300: A Promising Anti-Casein Kinase 2 (CK2) Peptide for Cancer Targeted Therapy
2015 · Silvio E. Perea, Yasser Perera, et al. · Springer eBooks · 5
Molecular detection of circulating tyrosinase mRNA: Optimization in a preclinical xenograft mouse melanoma model and further evaluation in samples from advanced melanoma patients
2008 · Mariano Gabri, Valeria Vazquez, et al. · International Journal of Molecular Medicine · 5
PDF
Active Specific Immunotherapy with Racotumomab in the Treatment of Advanced
2012 · A. Macías, S. Alfonso, et al. · Annals of Oncology · 4
Active immunotherapy in patients with progressive disease (PD) after first-line therapy: Racotumomab experience.
2013 · Roberto E Gomez, Saily Alfonso, et al. · Journal of Clinical Oncology · 3
Pharmacovigilance of a Rituximab Biosimilar (Novex) in Argentina
2016 · Gustavo Milone, Francisco Fernandez, et al. · Blood · 2
Monitoreo ambulatorio de presión arterial (mapa) y duración del efecto antihipertensivo: un estudio con una nueva forma farmacéutica de losartán de liberación sostenida (CRONOS)
2012 · Mario Bendersky, Luis Juncos, et al. · Revista de la Facultad de Ciencias Médicas de Córdoba · 2
Pharmovigilance of Rituximab Biosimilar in the Treatment of Lymphomas in Argentina
2017 · G. Milone, M.I. Penna, et al. · Hematological Oncology · 1
PDF
Supplementary Table S1 from Anticancer peptide CIGB-300 binds to nucleophosmin/B23, impairs its CK2-mediated phosphorylation, and leads to apoptosis through its nucleolar disassembly activity
2023 · Yasser Perera, Hernán G. Farina, et al.
PDF
Data from Anticancer peptide CIGB-300 binds to nucleophosmin/B23, impairs its CK2-mediated phosphorylation, and leads to apoptosis through its nucleolar disassembly activity
2023 · Yasser Perera, Hernán G. Farina, et al.
Data from Anticancer peptide CIGB-300 binds to nucleophosmin/B23, impairs its CK2-mediated phosphorylation, and leads to apoptosis through its nucleolar disassembly activity
2023 · Yasser Perera, Hernán G. Farina, et al.
Abstract P6-11-07: Perioperative administration of desmopressin (dDAVP) in breast cancer patients: A phase II dose-escalation study
2015 · Ruth S Weinberg, Marcelo O Grecco, et al. · Cancer Research
Inmunoterapia con Racotumomab: Un nuevo tratamiento del cáncer de pulmón de células no pequeñas
2013 · María Inés Penna, Marcelo D. Guthmann, et al. · Oncología Clínica
PDF
Works count: 28
Citation count: 668
H-index: 11
I10-index: 12
Year
Topic
Type